AC
KYMR icon

Armistice Capital’s Kymera Therapeutics KYMR Stock Holding History

Armistice Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Buy
106,272
+22,396
+27% +$1.92M 0.15% 94
2026
Q1 		$6.99M Buy
83,876
+2,711
+3% +$215K 0.12% 107
2025
Q4 		$6.32M Buy
+81,165
New +$5.48M 0.08% 121

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Armistice Capital's KYMR Position: Q2 2026 in Review

Armistice Capital increased its Kymera Therapeutics (KYMR) stake by 27% in Q2 2026, buying an estimated $1.92M and bringing the position to 106,272 shares worth $12.2M. The position accounts for 0.15% of the portfolio, ranked #94.

Armistice Capital first reported a position in KYMR in Q4 2025 and has held it in 3 quarters since. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Armistice Capital held 106,272 shares of Kymera Therapeutics worth $12.2M as of Q2 2026.
  • Armistice Capital bought 22,396 Kymera Therapeutics shares in Q2 2026, an estimated $1.92M.
  • Kymera Therapeutics made up 0.15% of Armistice Capital's portfolio in Q2 2026, its #94 holding.
  • Armistice Capital first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.